Glucocorticoid therapy for nonclassic congenital adrenal hyperplasia in women
- Autores: Tereshchenko I.V.1
-
Afiliações:
- Academician E.A. Vagner Perm State Medical University, Ministry of Health of Russia
- Edição: Nº 4 (2016)
- Páginas: 101-106
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247677
- DOI: https://doi.org/10.18565/aig.2016.4.101-106
- ID: 247677
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Objective. To analyze the impact of glucocorticoid (GC) therapy on the reproductive system, the course of pregnancy and labor, fetal development in patients with nonclassic congenital adrenal hyperplasia (NCCAH). Subject and methods. Reproductive system diseases and hormonal status were investigated in 46 women with NCCAH. All the women were treated with GC. Jointly with gynecologists, the investigators monitored the course of pregnancy and labor and fetal status in 43 women during prednisolone therapy. Results. The patients with NCCAH were observed to have reproductive system diseases caused by hypersecretion of the adrenal androgen 17α-OH progesterone (17 OH-n). GC treatment restored fertility. Conclusion. Adrenal androgen hypersecretion in patients with NCCAH gives rise to reproductive disorders and infertility. It is necessary to initiate suppressive (and replacement) therapy with GC and to normalize blood 17-OH-n levels in such patients in adolescence. Prednisolone therapy is certain to be performed in pregnancy to prevent miscarriage. In this case, prednisolone has no effect on fetal development.
Texto integral
Sobre autores
Irina Tereshchenko
Academician E.A. Vagner Perm State Medical University, Ministry of Health of Russia
Email: i_v_t@bk.ru
MD, professor of endocrinology and clinical pharmacology
Bibliografia
- Дедов И.И., Мельниченко ЕА., ред.Эндокринология. Национальное руководство. М.: ГЭОТАР-Медиа; 2013. 752с. [Dedov I.I., Melnichenko G.A., eds. Endocrinology. National guideline. Moscow: GEOTAR Media; 2013 752p. (in Russian)]
- Bidet M., Bellanné-Chantelot C., Galand-Portier M.B., Golmard L., Tardy V., Morel Y. et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 2010; 95(3): 1182-90.
- Kamoun M., Feki M.M., Sfar M.H., Abid M. Congenital adrenal hyperplasia: treatment and outcomes. Indian J. Endocrinol. Metab. 2013; 17(Suppl.1): 14-7.
- Krone N., Rose I.T., Willis D.S., Hodson J., Wild S.H., Doherty E.J. et al. Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) Cohort. J. Clin. Endocrinol. Metab. 2013; 98(2): E346-54.
- Mnif M. F., Kamoun M., Kacem F.H., Mnif F., Charfi N., Naceur B.B. et al. Reproductive outcomes of female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Indian J. Endocrinol. Metab. 2013; 17(5): 790-3.
- Lockshin M.D., Sammaritano L.R. Corticosteroids during pregnancy. Scand. J. Rheumatol. 1998; Suppl.107: 136-8.
- Lunghi L., Pavan B., Biondi C., Paolillo R., Valerio A., Vesce F. et al. Use of glucocorticoids in pregnancy. Curr. Pharm. Des. 2010; 16(32): 3616-37.
- Kalra S., Kalra B., Gupta Y. Glycemic management after antenatal corticosteroid therapy. North Am. J. Med. Sci. 2014; 6(2): 71-6.
- Дедов И.И., Мельниченко Г.А., ред. Эндокринология. Клинические рекомендации. 2-е изд. М.: ГЭОТАР-Медиа; 2012. 368с. [Dedov I.I., Melnichenko G.A., eds. Endocrinology. Clinical guidelines. 2nd ed. Moscow: GEOTAR Media; 2012. 368p. (in Russian)]
- Мельниченко Г.А., Семичева Т.В., Фадеев В.В., Чеботникова Т.В. Применение глюкокортикоидов во время беременности. Вестник репродуктивного здоровья. 2008; 7: 7-17. [Melnichenko G.A., Semicheva T.V., Fadeev V.V., Chebotnikova T.V. The use of glucocorticoids during pregnancy. Vestnik reproduktivnogo zdorovya. 2008; 7: 7-17. (in Russian)]
- Reisch N. Substitution therapy in adult patients with congenital adrenal hyperplasia. Best Pract. Res. Clin. Endocrinol. Metab. 2015; 29(1): 33-45.
- Witchel S.F., Azziz R. Congenital adrenal hyperplasia. J. Pediatr. Adolesc. Gynecol. 2011; 24(3): 116-26.
- McCann-Crosby B., Chen M.J., Lyons S.K., Lin Y., Axelrad M., Dietrich J.E. et al. Nonclassical congenital adrenal hyperplasia: targets of treatment and transition. Pediatr. Endocrinol. Rev. 2014; 12(2): 224-38.
- Pignate Ui D. Non-classic adrenal hyperplasia due to the deficiency of 21-hydroxylase and its relation to polycystic ovarian syndrome. Front. Horm. Res. 2013; 40: 158-70.
- Trapp C.M., Oberfield S.E. Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids. 2012; 77(4): 342-6.
- Debono M., Mallappa A., Gounden V., Nella A.A., Harrison R.F., Crutchfield C.A. et al. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. Eur. J. Endocrinol. 2015; 173(6): 727-37.
Arquivos suplementares
